Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial

Abstract

In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.